Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration

International Journal of Antimicrobial Agents

Volumn 43, Issue 4, 2014, Pages 343-348

  Varghese, Julie M ^a   Jarrett, Paul ^b   Boots, Robert J ^a,b   Kirkpatrick, Carl M J ^c   Lipman, Jeffrey ^a,b   Roberts, Jason A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

CRRT; Microdialysis; Pharmacodynamics; Pharmacokinetics; Target site; Lactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INTERSTITIAL FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; YOUNG ADULT; ACUTE KIDNEY INJURY; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CRITICAL ILLNESS; EXTRACELLULAR FLUID; HALF LIFE TIME; HEMOFILTRATION; MORTALITY; SEPSIS; URINE;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CRITICAL ILLNESS; EXTRACELLULAR FLUID; FEMALE; HALF-LIFE; HEMOFILTRATION; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; SEPSIS;

EID: 84897972263     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.01.009     Document Type: Article

References (30)

1. A. Gin, L. Dilay, J.A. Karlowsky, A. Walkty, E. Rubinstein, and G.G. Zhanel Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination Expert Rev Anti Infect Ther 5 2007 365 383
2. S. Uchino, J.A. Kellum, R. Bellomo, G.S. Doig, H. Morimatsu, and S. Morgera et al. Acute renal failure in critically ill patients: a multinational, multicenter study JAMA 294 2005 813 818
3. E.A.J. Hoste, and M. Schurgers Epidemiology of acute kidney injury: how big is the problem? Crit Care Med 36 4 Suppl 2008 S146 S151
4. R. Bellomo, A. Cass, L. Cole, S. Finfer, M. Gallagher, and S. Lo et al. Intensity of continuous renal-replacement therapy in critically ill patients N Engl J Med 361 2009 1627 1638
5. A. Kumar, D. Roberts, K.E. Wood, B. Light, J.E. Parrillo, and S. Sharma et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 34 2006 1589 1596
6. J. Garnacho-Montero, J.L. Garcia-Garmendia, A. Barrero-Almodovar, F.J. Jimenez-Jimenez, C. Perez-Paredes, and C. Ortiz-Leyba Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis Crit Care Med 31 2003 2742 2751
7. G.L. Drusano Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' Nat Rev Microbiol 2 2004 289 300
8. C. Joukhadar, M. Frossard, B.X. Mayer, M. Brunner, N. Klein, and P. Siostrzonek et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock Crit Care Med 29 2001 385 391
9. J.A. Roberts, M.S. Roberts, T.A. Robertson, A.J. Dalley, and J. Lipman Piperacillin penetration into tissue of critically ill patients with sepsis - bolus versus continuous administration? Crit Care Med 37 2009 926 933
10. J.A. Roberts, C.M.J. Kirkpatrick, M.S. Roberts, T.A. Robertson, A.J. Dalley, and J. Lipman Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution J Antimicrob Chemother 64 2009 142 150
11. M. Muller Science Medicine, and the future: microdialysis BMJ 324 2002 588 591
12. C. Joukhadar, N. Klein, B.X. Mayer, N. Kreischitz, G. Delle-Karth, and P. Palkovits et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis Crit Care Med 30 2002 1478 1482
13. R. Sauermann, G. Delle-Karth, C. Marsik, I. Steiner, M. Zeitlinger, and B.X. Mayer-Helm et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients Antimicrob Agents Chemother 49 2005 650 655
14. T.S. Van der Werf, P.O. Mulder, J.G. Zijlstra, D.R. Uges, and C.A. Stegeman Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH) Intensive Care Med 23 1997 873 877
15. M. Valtonen, E. Tiula, O. Takkunen, J.T. Backman, and P.J. Neuvonen Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure J Antimicrob Chemother 48 2001 881 885
16. S.C. Mueller, J. Majcher-Peszynska, H. Hickstein, A. Francke, A. Pertschy, and M. Schulz et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis Antimicrob Agents Chemother 46 2002 1557 1560
17. A. Arzuaga, J. Maynar, A.R. Gascon, A. Isla, E. Corral, and F. Fonseca et al. Influence of renal function on the pharmacokinetics of piperacillin/ tazobactam in intensive care unit patients during continuous venovenous hemofiltration J Clin Pharmacol 45 2005 168 176
18. S.R. Bauer, C. Salem, M.J. Connor, J. Groszek, M.E. Taylor, and P. Wei et al. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT Clin J Am Soc Nephrol 7 2012 452 457
19. A. De la Peña, P. Liu, and H. Derendorf Microdialysis in peripheral tissues Adv Drug Deliv Rev 45 2000 189 216
20. M.R. Bouw, and M. Hammarlund-Udenaes Methodological aspects of the use of a calibrator in in vivo microdialysis - further development of a retrodialysis method Pharm Res 15 1998 1673 1679
21. ®: product information; http://www.fda.gov/ ohrms/dockets/dockets/06p0195/06P-0195-EC1-Attach-1. pdf [accessed 30 October 2013].
22. G. Wong, S. Briscoe, S. Adnan, B. McWhinney, J. Ungerer, and J. Lipman et al. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57 2013 6165 6170
23. H.M. Bryson, and R.N. Brogden Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential Drugs 47 1994 506 535
24. F. Tomaselli, P. Dittrich, A. Maier, M. Woltsche, V. Matzi, and J. Pinter et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis Br J Clin Pharmacol 55 2003 620 624
25. J.A. Roberts, and J. Lipman Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis Clin Pharmacokinet 45 2006 755 773
26. F. Sörgel, and M. Kinzig The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam J Antimicrob Chemother 31 Suppl. A 1993 39 60
27. L. Seyler, F. Cotton, F.S. Taccone, D. De Backer, P. Macours, and J.L. Vincent et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy Crit Care 15 2011 R137
28. J.F. Westphal, J.M. Brogard, F. Caro-Sampara, M. Adloff, J.F. Blickle, and H. Monteil et al. Assessment of biliary excretion of piperacillin-tazobactam in humans Antimicrob Agents Chemother 41 1997 1636 1640
29. J.M. Brogard, F. Jehl, J.F. Blickle, M. Dorner, J.P. Arnaud, and H. Monteil Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in men Int J Clin Pharmacol Ther Toxicol 28 1990 462 470
30. M.K. Kim, D. Xuan, R. Quintiliani, C.H. Nightingale, and D.P. Nicolau Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam J Antimicrob Chemother 48 2001 259 267